VCYT

insider transactions

VERACYTE, INC. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-482.2K

0 buy · 482.2K sell

Net value · 365d

-$21.1M

$0 in · $21.1M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 482.2K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 11, 26

Shafer David Brent

Director

$0

5.3K sh

Own +20%
Grant·A
Jun 11, 26

Miller Thomas F.

Director

$0

5.3K sh

Own +20%
Grant·A
Jun 11, 26

JONES EVAN/ FA

Director

$0

5.3K sh

Own +18%
Grant·A
Jun 11, 26

Holstein Jens

Director

$0

5.3K sh

Own +19%
Grant·A
Jun 11, 26

EPSTEIN ROBERT S

Director

$0

5.3K sh

Own +10%
Grant·A
Jun 11, 26

EASTHAM KARIN

Director

$0

5.3K sh

Own +39%
Grant·A
Jun 11, 26

Bhanji Muna

Director

$0

5.3K sh

Own +13%
Grant·A
Jun 11, 26

Barr Eliav

Director

$0

5.3K sh

Own +10%
Exercise·M
Jun 4, 26

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$0

138.1K sh

Own New
Sell·S
Jun 4, 26

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$6.9M

138.1K sh · $50.12

Own -24%
Exercise·M
Jun 4, 26

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$5.1M

138.1K sh · $36.60

Own +31%
Sell·S
Jun 4, 26

McGuire Annie

EVP, General Counsel · 10b5-1

$89.0K

1.8K sh · $50.12

Own -1%
Sell·S
Jun 4, 26

McGuire Annie

EVP, General Counsel · 10b5-1

$69.0K

1.4K sh · $49.31

Own -1%
Sell·S
Jun 4, 26

Leite John

Global Chief Commercial Off · 10b5-1

$699.7K

14.0K sh · $50.07

Own -10%
Sell·S
Jun 4, 26

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$98.2K

2.0K sh · $50.09

Own -1%
Sell·S
Jun 4, 26

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$78.9K

1.6K sh · $49.28

Own -1%
Other·F
Jun 2, 26

Wygant Jonathan

VP, Chief Accounting Officer

$65.1K

1.4K sh · $47.80

Own -3%
Other·F
Jun 2, 26

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$430.8K

9.0K sh · $47.80

Own -2%
Other·F
Jun 2, 26

McGuire Annie

EVP, General Counsel · 10b5-1

$157.4K

3.3K sh · $47.80

Own -2%
Other·F
Jun 2, 26

Leite John

Global Chief Commercial Off · 10b5-1

$194.0K

4.1K sh · $47.80

Own -3%
Other·F
Jun 2, 26

Febbo Phillip G.

Chief Scientific & Med Officer · 10b5-1

$178.3K

3.7K sh · $47.80

Own -2%
Other·F
Jun 2, 26

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$176.5K

3.7K sh · $47.80

Own -2%
Exercise·M
May 22, 26

Wygant Jonathan

VP, Chief Accounting Officer

$0

24.0K sh

Own New
Sell·S
May 22, 26

Wygant Jonathan

VP, Chief Accounting Officer

$1.1M

24.0K sh · $45.40

Own -35%
Exercise·M
May 22, 26

Wygant Jonathan

VP, Chief Accounting Officer

$595.2K

24.0K sh · $24.80

Own +53%
Sell·S
May 20, 26

EPSTEIN ROBERT S

Director · 10b5-1

$440.1K

10.0K sh · $44.01

Own -16%
Sell·S
May 6, 26

McGuire Annie

SVP, General Counsel · 10b5-1

$204.1K

5.1K sh · $40.00

Own -3%
Sell·S
May 6, 26

McGuire Annie

SVP, General Counsel · 10b5-1

$194.1K

5.1K sh · $38.05

Own -3%
Grant·A
Apr 10, 26

Haas Kevin Richard

Chief Dev and Tech Officer

$0

44.2K sh

Own New
Grant·A
Mar 6, 26

Chambers Rebecca KEY

Chief Financial Officer

$0

13.2K sh

Own +8%
Grant·A
Mar 6, 26

Chambers Rebecca KEY

Chief Financial Officer

$0

36.2K sh

Own +28%
Grant·A
Mar 6, 26

McGuire Annie

SVP, General Counsel

$0

26.3K sh

Own +21%
Grant·A
Mar 6, 26

McGuire Annie

SVP, General Counsel

$0

32.9K sh

Own +35%
Grant·A
Mar 6, 26

Stapley Marc KEY

Chief Executive Officer

$0

92.1K sh

Own +26%
Grant·A
Mar 6, 26

Wygant Jonathan

VP, Chief Accounting Officer

$0

10.5K sh

Own +30%
Grant·A
Mar 6, 26

Febbo Phillip G.

Chief Scientific & Med Officer

$0

29.6K sh

Own +25%
Grant·A
Mar 6, 26

Febbo Phillip G.

Chief Scientific & Med Officer

$0

6.6K sh

Own +4%
Grant·A
Mar 6, 26

Leite John

Chief Commercial Officer-CLIA

$0

36.2K sh

Own +34%
Grant·A
Mar 6, 26

Leite John

Chief Commercial Officer-CLIA

$0

6.6K sh

Own +5%
Sell·S
Mar 4, 26

McGuire Annie

SVP, General Counsel · 10b5-1

$60.5K

1.7K sh · $36.34

Own -2%
Sell·S
Mar 4, 26

McGuire Annie

SVP, General Counsel · 10b5-1

$176.2K

5.0K sh · $35.29

Own -5%
Sell·S
Mar 4, 26

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$156.4K

4.4K sh · $35.55

Own -3%
Sell·S
Mar 4, 26

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$506.5K

13.9K sh · $36.33

Own -10%
Sell·S
Mar 4, 26

Leite John

Chief Commercial Officer-CLIA · 10b5-1

$185.1K

5.3K sh · $35.19

Own -5%
Sell·S
Mar 4, 26

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$684.3K

19.2K sh · $35.56

Own -5%
Sell·S
Mar 4, 26

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$953.4K

26.3K sh · $36.28

Own -7%
Other·F
Mar 2, 26

Wygant Jonathan

VP, Chief Accounting Officer

$108.2K

3.0K sh · $36.01

Own -8%
Other·F
Mar 2, 26

Leite John

Chief Commercial Officer-CLIA

$270.7K

7.5K sh · $36.01

Own -6%
Other·F
Mar 2, 26

Chambers Rebecca KEY

Chief Financial Officer

$260.5K

7.2K sh · $36.01

Own -5%
Other·F
Mar 2, 26

Febbo Phillip G.

Chief Scientific & Med Officer · 10b5-1

$217.3K

6.0K sh · $36.01

Own -4%
Sell·S
Mar 2, 26

Febbo Phillip G.

Chief Scientific & Med Officer · 10b5-1

$485.4K

13.4K sh · $36.16

Own -10%
Other·F
Mar 2, 26

Stapley Marc KEY

Chief Executive Officer

$700.6K

19.5K sh · $36.01

Own -5%
Other·F
Mar 2, 26

McGuire Annie

SVP, General Counsel

$248.5K

6.9K sh · $36.01

Own -6%
Other·F
Feb 26, 26

Leite John

Chief Commercial Officer-CLIA

$345.1K

8.9K sh · $38.75

Own -7%
Grant·A
Feb 26, 26

Leite John

Chief Commercial Officer-CLIA

$0

47.1K sh

Own +57%
Other·F
Feb 26, 26

McGuire Annie

SVP, General Counsel

$421.1K

10.9K sh · $38.75

Own -9%
Grant·A
Feb 26, 26

McGuire Annie

SVP, General Counsel

$0

51.0K sh

Own +75%
Other·F
Feb 26, 26

Stapley Marc KEY

Chief Executive Officer

$1.4M

35.8K sh · $38.75

Own -8%
Grant·A
Feb 26, 26

Stapley Marc KEY

Chief Executive Officer

$0

139.1K sh

Own +44%
Grant·A
Feb 26, 26

Febbo Phillip G.

Chief Scientific & Med Officer

$0

71.8K sh

Own +80%
Other·F
Feb 26, 26

Febbo Phillip G.

Chief Scientific & Med Officer

$948.8K

24.5K sh · $38.75

Own -15%
Other·F
Feb 26, 26

Chambers Rebecca KEY

Chief Financial Officer

$466.9K

12.0K sh · $38.75

Own -7%
Grant·A
Feb 26, 26

Chambers Rebecca KEY

Chief Financial Officer

$0

59.3K sh

Own +54%
Sell·S
Dec 16, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$4.4K

100 sh · $43.68

Own -0%
Sell·S
Dec 16, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$458.9K

10.6K sh · $43.13

Own -14%
Exercise·M
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$0

10.0K sh

Own New
Exercise·M
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$0

10.0K sh

Own New
Sell·S
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$284.6K

6.4K sh · $44.52

Own -19%
Sell·S
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$587.1K

12.8K sh · $45.84

Own -47%
Sell·S
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$37.3K

800 sh · $46.59

Own -6%
Exercise·M
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$76.0K

10.0K sh · $7.60

Own +42%
Exercise·M
Dec 5, 25

EASTHAM KARIN

Director · 10b5-1

$79.4K

10.0K sh · $7.94

Own +74%
Sell·S
Dec 4, 25

Leite John

Chief Commercial Officer-CLIA · 10b5-1

$60.7K

1.3K sh · $47.51

Own -2%
Sell·S
Dec 4, 25

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$152.5K

3.2K sh · $47.35

Own -1%
Sell·S
Dec 4, 25

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$208.6K

4.4K sh · $46.90

Own -1%
Sell·S
Dec 4, 25

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$397.9K

8.5K sh · $46.61

Own -7%
Sell·S
Dec 4, 25

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$224.0K

4.7K sh · $47.25

Own -4%
Sell·S
Dec 4, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$33.4K

702 sh · $47.51

Own -1%
Sell·S
Dec 4, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$33.9K

720 sh · $47.10

Own -1%
Other·F
Dec 2, 25

Leite John

Chief Commercial Officer-CLIA · 10b5-1

$133.9K

2.9K sh · $46.16

Own -3%
Other·F
Dec 2, 25

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$365.3K

7.9K sh · $46.16

Own -2%
Other·F
Dec 2, 25

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$156.2K

3.4K sh · $46.16

Own -3%
Other·F
Dec 2, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$140.9K

3.1K sh · $46.16

Own -4%
Other·F
Dec 2, 25

Febbo Phillip G.

Chief Scientific & Med Officer

$136.4K

3.0K sh · $46.16

Own -3%
Other·F
Dec 2, 25

Wygant Jonathan

VP, Chief Accounting Officer

$61.2K

1.3K sh · $46.16

Own -3%
Sell·S
Nov 25, 25

Leite John

Chief Commercial Officer-CLIA · 10b5-1

$140.4K

2.8K sh · $50.00

Own -3%
Sell·S
Nov 25, 25

JONES EVAN/ FA

Director · 10b5-1

$55.6K

1.1K sh · $50.25

Own -4%
Sell·S
Nov 20, 25

Holstein Jens

Director · 10b5-1

$63.1K

1.5K sh · $43.21

Own -5%
Sell·S
Nov 20, 25

Holstein Jens

Director · 10b5-1

$61.1K

1.5K sh · $40.95

Own -4%
Sell·S
Nov 20, 25

Holstein Jens

Director · 10b5-1

$299.4K

7.0K sh · $42.48

Own -20%
Sell·S
Nov 10, 25

Wygant Jonathan

VP, Chief Accounting Officer

$216.0K

5.1K sh · $42.33

Own -12%
Sell·S
Nov 7, 25

Wygant Jonathan

VP, Chief Accounting Officer

$233.9K

5.8K sh · $40.21

Own -12%
Exercise·M
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$0

10.0K sh

Own New
Exercise·M
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$0

10.0K sh

Own New
Exercise·M
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$0

10.0K sh

Own New
Sell·S
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$17.0K

408 sh · $41.74

Own -1%
Exercise·M
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$52.8K

10.0K sh · $5.28

Own +23%
Sell·S
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$1.1M

24.3K sh · $45.73

Own -44%
Sell·S
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$264.7K

5.9K sh · $45.07

Own -10%
Sell·S
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$474.7K

10.8K sh · $43.80

Own -15%
Sell·S
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$48.5K

1.1K sh · $43.03

Own -2%
Sell·S
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$30.5K

657 sh · $46.38

Own -2%
Exercise·M
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$76.0K

10.0K sh · $7.60

Own +16%
Exercise·M
Nov 5, 25

JONES EVAN/ FA

Director · 10b5-1

$79.4K

10.0K sh · $7.94

Own +19%
Sell·S
Nov 5, 25

EASTHAM KARIN

Director · 10b5-1

$387.2K

9.7K sh · $40.02

Own -42%
Sell·S
Nov 5, 25

Chambers Rebecca KEY

Chief Financial Officer · 10b5-1

$287.0K

7.0K sh · $41.00

Own -5%
Sell·S
Nov 5, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$258.6K

6.5K sh · $40.00

Own -7%
Grant·A
Oct 28, 25

Wygant Jonathan

VP, Chief Accounting Officer

$0

2.9K sh

Own +6%
Sell·S
Oct 6, 25

Febbo Phillip G.

Chief Scientific & Med Officer · 10b5-1

$300.7K

8.3K sh · $36.02

Own -8%
Sell·S
Oct 1, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$75.6K

2.2K sh · $35.00

Own -2%
Sell·S
Oct 1, 25

Leite John

Chief Commercial Officer-CLIA · 10b5-1

$88.9K

2.5K sh · $35.00

Own -3%
Exercise·M
Oct 1, 25

EPSTEIN ROBERT S

Director · 10b5-1

$0

10.0K sh

Own New
Sell·S
Oct 1, 25

EPSTEIN ROBERT S

Director · 10b5-1

$753.3K

21.5K sh · $35.08

Own -26%
Exercise·M
Oct 1, 25

EPSTEIN ROBERT S

Director · 10b5-1

$79.4K

10.0K sh · $7.94

Own +14%
Sell·S
Sep 19, 25

McGuire Annie

SVP, General Counsel · 10b5-1

$76.9K

2.3K sh · $33.69

Own -2%
Sell·S
Sep 4, 25

Stapley Marc KEY

Chief Executive Officer · 10b5-1

$233.2K

7.7K sh · $30.41

Own -2%
Other·F
Sep 2, 25

Stapley Marc KEY

Chief Executive Officer

$238.3K

7.9K sh · $30.11

Own -2%
Other·F
Sep 2, 25

Chambers Rebecca KEY

Chief Financial Officer

$161.7K

5.4K sh · $30.11

Own -4%
Other·F
Sep 2, 25

Febbo Phillip G.

Chief Scientific & Med Officer

$89.0K

3.0K sh · $30.11

Own -3%
Other·F
Sep 2, 25

McGuire Annie

SVP, General Counsel

$105.6K

3.5K sh · $30.11

Own -4%
Other·F
Sep 2, 25

Leite John

Chief Commercial Officer-CLIA

$87.4K

2.9K sh · $30.11

Own -3%
Other·F
Sep 2, 25

Wygant Jonathan

VP, Chief Accounting Officer

$49.6K

1.6K sh · $30.11

Own -3%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	Shafer David Brent	Director	Grant A	5.3K	+20%	—	$0
Jun 11, 2026	Miller Thomas F.	Director	Grant A	5.3K	+20%	—	$0
Jun 11, 2026	JONES EVAN/ FA	Director	Grant A	5.3K	+18%	—	$0
Jun 11, 2026	Holstein Jens	Director	Grant A	5.3K	+19%	—	$0
Jun 11, 2026	EPSTEIN ROBERT S	Director	Grant A	5.3K	+10%	—	$0
Jun 11, 2026	EASTHAM KARIN	Director	Grant A	5.3K	+39%	—	$0
Jun 11, 2026	Bhanji Muna	Director	Grant A	5.3K	+13%	—	$0
Jun 11, 2026	Barr Eliav	Director	Grant A	5.3K	+10%	—	$0
Jun 4, 2026	Stapley Marc KEY 10b5-1	Chief Executive Officer	Exercise M	138.1K	New	—	$0
Jun 4, 2026	Stapley Marc KEY 10b5-1	Chief Executive Officer	Sell S	138.1K	-24%	$50.12	$6.9M
Jun 4, 2026	Stapley Marc KEY 10b5-1	Chief Executive Officer	Exercise M	138.1K	+31%	$36.60	$5.1M
Jun 4, 2026	McGuire Annie 10b5-1	EVP, General Counsel	Sell S	1.8K	-1%	$50.12	$89.0K
Jun 4, 2026	McGuire Annie 10b5-1	EVP, General Counsel	Sell S	1.4K	-1%	$49.31	$69.0K
Jun 4, 2026	Leite John 10b5-1	Global Chief Commercial Off	Sell S	14.0K	-10%	$50.07	$699.7K
Jun 4, 2026	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	2.0K	-1%	$50.09	$98.2K
Jun 4, 2026	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	1.6K	-1%	$49.28	$78.9K
Jun 2, 2026	Wygant Jonathan	VP, Chief Accounting Officer	Other F	1.4K	-3%	$47.80	$65.1K
Jun 2, 2026	Stapley Marc KEY 10b5-1	Chief Executive Officer	Other F	9.0K	-2%	$47.80	$430.8K
Jun 2, 2026	McGuire Annie 10b5-1	EVP, General Counsel	Other F	3.3K	-2%	$47.80	$157.4K
Jun 2, 2026	Leite John 10b5-1	Global Chief Commercial Off	Other F	4.1K	-3%	$47.80	$194.0K
Jun 2, 2026	Febbo Phillip G. 10b5-1	Chief Scientific & Med Officer	Other F	3.7K	-2%	$47.80	$178.3K
Jun 2, 2026	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Other F	3.7K	-2%	$47.80	$176.5K
May 22, 2026	Wygant Jonathan	VP, Chief Accounting Officer	Exercise M	24.0K	New	—	$0
May 22, 2026	Wygant Jonathan	VP, Chief Accounting Officer	Sell S	24.0K	-35%	$45.40	$1.1M
May 22, 2026	Wygant Jonathan	VP, Chief Accounting Officer	Exercise M	24.0K	+53%	$24.80	$595.2K
May 20, 2026	EPSTEIN ROBERT S 10b5-1	Director	Sell S	10.0K	-16%	$44.01	$440.1K
May 6, 2026	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	5.1K	-3%	$40.00	$204.1K
May 6, 2026	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	5.1K	-3%	$38.05	$194.1K
Apr 10, 2026	Haas Kevin Richard	Chief Dev and Tech Officer	Grant A	44.2K	New	—	$0
Mar 6, 2026	Chambers Rebecca KEY	Chief Financial Officer	Grant A	13.2K	+8%	—	$0
Mar 6, 2026	Chambers Rebecca KEY	Chief Financial Officer	Grant A	36.2K	+28%	—	$0
Mar 6, 2026	McGuire Annie	SVP, General Counsel	Grant A	26.3K	+21%	—	$0
Mar 6, 2026	McGuire Annie	SVP, General Counsel	Grant A	32.9K	+35%	—	$0
Mar 6, 2026	Stapley Marc KEY	Chief Executive Officer	Grant A	92.1K	+26%	—	$0
Mar 6, 2026	Wygant Jonathan	VP, Chief Accounting Officer	Grant A	10.5K	+30%	—	$0
Mar 6, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Grant A	29.6K	+25%	—	$0
Mar 6, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Grant A	6.6K	+4%	—	$0
Mar 6, 2026	Leite John	Chief Commercial Officer-CLIA	Grant A	36.2K	+34%	—	$0
Mar 6, 2026	Leite John	Chief Commercial Officer-CLIA	Grant A	6.6K	+5%	—	$0
Mar 4, 2026	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	1.7K	-2%	$36.34	$60.5K
Mar 4, 2026	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	5.0K	-5%	$35.29	$176.2K
Mar 4, 2026	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	4.4K	-3%	$35.55	$156.4K
Mar 4, 2026	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	13.9K	-10%	$36.33	$506.5K
Mar 4, 2026	Leite John 10b5-1	Chief Commercial Officer-CLIA	Sell S	5.3K	-5%	$35.19	$185.1K
Mar 4, 2026	Stapley Marc KEY 10b5-1	Chief Executive Officer	Sell S	19.2K	-5%	$35.56	$684.3K
Mar 4, 2026	Stapley Marc KEY 10b5-1	Chief Executive Officer	Sell S	26.3K	-7%	$36.28	$953.4K
Mar 2, 2026	Wygant Jonathan	VP, Chief Accounting Officer	Other F	3.0K	-8%	$36.01	$108.2K
Mar 2, 2026	Leite John	Chief Commercial Officer-CLIA	Other F	7.5K	-6%	$36.01	$270.7K
Mar 2, 2026	Chambers Rebecca KEY	Chief Financial Officer	Other F	7.2K	-5%	$36.01	$260.5K
Mar 2, 2026	Febbo Phillip G. 10b5-1	Chief Scientific & Med Officer	Other F	6.0K	-4%	$36.01	$217.3K
Mar 2, 2026	Febbo Phillip G. 10b5-1	Chief Scientific & Med Officer	Sell S	13.4K	-10%	$36.16	$485.4K
Mar 2, 2026	Stapley Marc KEY	Chief Executive Officer	Other F	19.5K	-5%	$36.01	$700.6K
Mar 2, 2026	McGuire Annie	SVP, General Counsel	Other F	6.9K	-6%	$36.01	$248.5K
Feb 26, 2026	Leite John	Chief Commercial Officer-CLIA	Other F	8.9K	-7%	$38.75	$345.1K
Feb 26, 2026	Leite John	Chief Commercial Officer-CLIA	Grant A	47.1K	+57%	—	$0
Feb 26, 2026	McGuire Annie	SVP, General Counsel	Other F	10.9K	-9%	$38.75	$421.1K
Feb 26, 2026	McGuire Annie	SVP, General Counsel	Grant A	51.0K	+75%	—	$0
Feb 26, 2026	Stapley Marc KEY	Chief Executive Officer	Other F	35.8K	-8%	$38.75	$1.4M
Feb 26, 2026	Stapley Marc KEY	Chief Executive Officer	Grant A	139.1K	+44%	—	$0
Feb 26, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Grant A	71.8K	+80%	—	$0
Feb 26, 2026	Febbo Phillip G.	Chief Scientific & Med Officer	Other F	24.5K	-15%	$38.75	$948.8K
Feb 26, 2026	Chambers Rebecca KEY	Chief Financial Officer	Other F	12.0K	-7%	$38.75	$466.9K
Feb 26, 2026	Chambers Rebecca KEY	Chief Financial Officer	Grant A	59.3K	+54%	—	$0
Dec 16, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	100	-0%	$43.68	$4.4K
Dec 16, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	10.6K	-14%	$43.13	$458.9K
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Exercise M	10.0K	New	—	$0
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Exercise M	10.0K	New	—	$0
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Sell S	6.4K	-19%	$44.52	$284.6K
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Sell S	12.8K	-47%	$45.84	$587.1K
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Sell S	800	-6%	$46.59	$37.3K
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Exercise M	10.0K	+42%	$7.60	$76.0K
Dec 5, 2025	EASTHAM KARIN 10b5-1	Director	Exercise M	10.0K	+74%	$7.94	$79.4K
Dec 4, 2025	Leite John 10b5-1	Chief Commercial Officer-CLIA	Sell S	1.3K	-2%	$47.51	$60.7K
Dec 4, 2025	Stapley Marc KEY 10b5-1	Chief Executive Officer	Sell S	3.2K	-1%	$47.35	$152.5K
Dec 4, 2025	Stapley Marc KEY 10b5-1	Chief Executive Officer	Sell S	4.4K	-1%	$46.90	$208.6K
Dec 4, 2025	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	8.5K	-7%	$46.61	$397.9K
Dec 4, 2025	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	4.7K	-4%	$47.25	$224.0K
Dec 4, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	702	-1%	$47.51	$33.4K
Dec 4, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	720	-1%	$47.10	$33.9K
Dec 2, 2025	Leite John 10b5-1	Chief Commercial Officer-CLIA	Other F	2.9K	-3%	$46.16	$133.9K
Dec 2, 2025	Stapley Marc KEY 10b5-1	Chief Executive Officer	Other F	7.9K	-2%	$46.16	$365.3K
Dec 2, 2025	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Other F	3.4K	-3%	$46.16	$156.2K
Dec 2, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Other F	3.1K	-4%	$46.16	$140.9K
Dec 2, 2025	Febbo Phillip G.	Chief Scientific & Med Officer	Other F	3.0K	-3%	$46.16	$136.4K
Dec 2, 2025	Wygant Jonathan	VP, Chief Accounting Officer	Other F	1.3K	-3%	$46.16	$61.2K
Nov 25, 2025	Leite John 10b5-1	Chief Commercial Officer-CLIA	Sell S	2.8K	-3%	$50.00	$140.4K
Nov 25, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	1.1K	-4%	$50.25	$55.6K
Nov 20, 2025	Holstein Jens 10b5-1	Director	Sell S	1.5K	-5%	$43.21	$63.1K
Nov 20, 2025	Holstein Jens 10b5-1	Director	Sell S	1.5K	-4%	$40.95	$61.1K
Nov 20, 2025	Holstein Jens 10b5-1	Director	Sell S	7.0K	-20%	$42.48	$299.4K
Nov 10, 2025	Wygant Jonathan	VP, Chief Accounting Officer	Sell S	5.1K	-12%	$42.33	$216.0K
Nov 7, 2025	Wygant Jonathan	VP, Chief Accounting Officer	Sell S	5.8K	-12%	$40.21	$233.9K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Exercise M	10.0K	New	—	$0
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Exercise M	10.0K	New	—	$0
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Exercise M	10.0K	New	—	$0
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	408	-1%	$41.74	$17.0K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Exercise M	10.0K	+23%	$5.28	$52.8K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	24.3K	-44%	$45.73	$1.1M
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	5.9K	-10%	$45.07	$264.7K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	10.8K	-15%	$43.80	$474.7K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	1.1K	-2%	$43.03	$48.5K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Sell S	657	-2%	$46.38	$30.5K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Exercise M	10.0K	+16%	$7.60	$76.0K
Nov 5, 2025	JONES EVAN/ FA 10b5-1	Director	Exercise M	10.0K	+19%	$7.94	$79.4K
Nov 5, 2025	EASTHAM KARIN 10b5-1	Director	Sell S	9.7K	-42%	$40.02	$387.2K
Nov 5, 2025	Chambers Rebecca KEY 10b5-1	Chief Financial Officer	Sell S	7.0K	-5%	$41.00	$287.0K
Nov 5, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	6.5K	-7%	$40.00	$258.6K
Oct 28, 2025	Wygant Jonathan	VP, Chief Accounting Officer	Grant A	2.9K	+6%	—	$0
Oct 6, 2025	Febbo Phillip G. 10b5-1	Chief Scientific & Med Officer	Sell S	8.3K	-8%	$36.02	$300.7K
Oct 1, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	2.2K	-2%	$35.00	$75.6K
Oct 1, 2025	Leite John 10b5-1	Chief Commercial Officer-CLIA	Sell S	2.5K	-3%	$35.00	$88.9K
Oct 1, 2025	EPSTEIN ROBERT S 10b5-1	Director	Exercise M	10.0K	New	—	$0
Oct 1, 2025	EPSTEIN ROBERT S 10b5-1	Director	Sell S	21.5K	-26%	$35.08	$753.3K
Oct 1, 2025	EPSTEIN ROBERT S 10b5-1	Director	Exercise M	10.0K	+14%	$7.94	$79.4K
Sep 19, 2025	McGuire Annie 10b5-1	SVP, General Counsel	Sell S	2.3K	-2%	$33.69	$76.9K
Sep 4, 2025	Stapley Marc KEY 10b5-1	Chief Executive Officer	Sell S	7.7K	-2%	$30.41	$233.2K
Sep 2, 2025	Stapley Marc KEY	Chief Executive Officer	Other F	7.9K	-2%	$30.11	$238.3K
Sep 2, 2025	Chambers Rebecca KEY	Chief Financial Officer	Other F	5.4K	-4%	$30.11	$161.7K
Sep 2, 2025	Febbo Phillip G.	Chief Scientific & Med Officer	Other F	3.0K	-3%	$30.11	$89.0K
Sep 2, 2025	McGuire Annie	SVP, General Counsel	Other F	3.5K	-4%	$30.11	$105.6K
Sep 2, 2025	Leite John	Chief Commercial Officer-CLIA	Other F	2.9K	-3%	$30.11	$87.4K
Sep 2, 2025	Wygant Jonathan	VP, Chief Accounting Officer	Other F	1.6K	-3%	$30.11	$49.6K

About VCYT insider trading

This page tracks insider transactions for VERACYTE, INC. (VCYT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.